[go: up one dir, main page]

WO2011019074A1 - Acide nucléique qui contrôle la fibrose de cellules ou d'organes - Google Patents

Acide nucléique qui contrôle la fibrose de cellules ou d'organes Download PDF

Info

Publication number
WO2011019074A1
WO2011019074A1 PCT/JP2010/063728 JP2010063728W WO2011019074A1 WO 2011019074 A1 WO2011019074 A1 WO 2011019074A1 JP 2010063728 W JP2010063728 W JP 2010063728W WO 2011019074 A1 WO2011019074 A1 WO 2011019074A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
fibrosis
cell
microrna
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2010/063728
Other languages
English (en)
Japanese (ja)
Inventor
伸晃 江藤
将矩 兼松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of WO2011019074A1 publication Critical patent/WO2011019074A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Definitions

  • the present invention relates to a cell or organ fibrosis control agent using a nucleic acid, a diagnostic or therapeutic agent for a disease caused by a fibrotic disorder, a cell or organ fibrosis control method, and a screening method for a cell or organ fibrosis control agent About.
  • MicroRNA which is a kind of nucleic acid, is a small non-coding single-stranded RNA consisting of about 22 nucleotides that are not translated into protein, and is known to exist in many organisms including humans (Non-Patent Documents). 1, 2). MicroRNAs are generated from genes that are transcribed into single or clustered microRNA precursors. In other words, the primary transcript, primary-microRNA (pri-miRNA), is first transcribed from the gene, and then in a stepwise process from pri-miRNA to mature microRNA, a precursor of about 70 bases with a characteristic hairpin structure. -microRNA (pre-miRNA) is generated from pri-miRNA. Furthermore, mature microRNA is generated from pre-miRNA by Dicer-mediated processing (Non-patent Document 3).
  • Mature microRNAs are thought to be involved in post-transcriptional control of gene expression by binding complementarily to the target mRNA and suppressing mRNA translation, or by degrading the mRNA.
  • the mechanism by which microRNA suppresses the expression of target mRNA is not completely clarified, an outline has been elucidated by recent studies.
  • MicroRNA binds to a partially complementary sequence in the 3'-untranslated region (3'-UTR) of the target mRNA, suppresses its translation, or suppresses expression by degrading the target mRNA To do.
  • 3'-UTR 3'-untranslated region
  • the above complementarity may not be perfect, it has been shown that complementarity of the second to eighth bases from the 5′-end side of the microRNA is particularly important.
  • Non-patent Document 4 Is sometimes referred to as a “seed sequence” (Non-patent Document 4). It has been shown that microRNAs with a common seed sequence suppress the expression of a common target mRNA even if other sequences are different. Therefore, RNA having microRNA-like activity can be designed by using a sequence complementary to the sequence present at the 3′-end of any mRNA as a seed sequence. Unlike siRNA, microRNA usually refers only to RNA that is “naturally present in cells”. Therefore, a microRNA-like sequence designed in this way may be particularly referred to as “artificial microRNA”.
  • the microRNA database miRBase (http://microrna.sanger.ac.uk/) contains 706 human, 547 mouse, and 286 rat microRNAs. .
  • miR-181 Non-patent Document 5
  • miR-375 involved in insulin secretion
  • Non-patent document 6 is only a small part, and many of them have unclear physiological activity.
  • studies using nematodes and Drosophila have revealed that microRNAs play various important roles in the development and differentiation of living organisms. There has been a report suggesting a relationship (Non-patent Document 7).
  • Fibrosis is a phenomenon in which the part called connective tissue that constitutes tissues such as internal organs grows abnormally and occurs in various tissues and organs such as lung, kidney, liver, heart, skin, blood vessels, and causes disease It is known. For example, when fibrosis occurs in the myocardium, abnormalities occur in the function of the heart, and symptoms such as dyspnea and increased heart rate (palpitations) appear. In addition, bone atrophy and degeneration in rheumatoid arthritis and the pathology of cirrhosis, which indicates fibrosis of the entire liver, are well known as examples of abnormal growth of the connective tissue, that is, fibrosis.
  • Tissue fibrosis is mainly caused by abnormal production of the extracellular matrix of fibroblasts present in the tissue, but the epithelial cells constituting the tissue are transformed into mesenchymal cells together with the extracellular matrix. It has been clarified that starting to produce a substrate also contributes, and these are called epithelial-mesenchymal transition (EMT) (Non-patent Document 8).
  • EMT epithelial-mesenchymal transition
  • MicroRNA research so far has been progressing mainly in cancer research, and in many cancers, microRNA expression is different from normal tissues, and cancer can be classified by microRNA expression profile analysis.
  • Non-Patent Document 9 It is also known that about half of the human microRNAs found so far exist in chromosomal abnormalities or fragile sites of chromosomes known in human cancer (Non-patent Document 10).
  • general immunosuppressive drugs such as corticosteroids and other anti-inflammatory treatments are currently used for treatment of organ fibrosis.
  • the mechanisms involved in controlling fibrosis appear to be a separate phenomenon from that of inflammation, and anti-inflammatory therapy is not always effective in reducing or preventing fibrosis. It cannot be said that the clinical needs are satisfied (Non-patent Document 11).
  • Non-patent Document 11 Thus, there is still a need to develop new therapies that modulate fibrotic disorders, including reducing or preventing fibrosis.
  • microRNA Since microRNA is involved in the control of the expression of various genes, abnormalities in microRNA are expected to be involved in various human diseases.
  • miR-15a / miR-16 cluster is included in chromosome 13q14, which is deleted in miR-29cB cell chronic lymphocytic leukemia (B-CLL), and this deletion is one of the causes of B-CLL. That are predicted to be connected (Non-patent Document 12).
  • B-CLL miR-29 and miR-181 expression is further reduced, and one of the targets is Tcl1, which is known as a proto-oncogene. (Non-patent Document 13) is known.
  • Non-patent Documents 14 and 15 expression of Let-7, which is one of microRNAs, is decreased, and one of its targets is Ras known as a proto-oncogene (Non-patent Documents 14 and 15).
  • microRNAs such as miR-127 and miR-124a is reduced by hypermethylation modification of genes in cancer, and Bcl6 and Cdk6 known as proto-oncogenes are the targets (Non-patent Document 16, 17).
  • Many microRNAs have decreased expression in cancer cells, but there are also microRNAs in which gene amplification and overexpression are seen in cancer cells. For example, in a region where gene amplification is observed in malignant lymphoma, there are 6 types of microRNA clusters (miR-17-92).
  • Non-patent Document 18 a gene called BIC, which has been previously overexpressed in Hodgkin's lymphoma and was a candidate oncogene that does not encode a protein, encodes miR-155 (Non-patent Document 19).
  • microRNAs whose expression changes in fibrotic organs, analyzing their functions, and elucidating the relationship with diseases.
  • finding microRNAs that promote or suppress fibrosis of cells or organs not only helps understand the mechanism of fibrosis, but also develops diagnostic and therapeutic agents for human organ fibrosis, and further It is expected to lead to new diagnostic methods and treatments for the fibrosis used.
  • An object of the present invention is to provide a nucleic acid and a fibrosis control agent useful for controlling fibrosis of cells or organs, and methods for using them.
  • the fibrosis regulator refers to a fibrosis inhibitor and a fibrosis promoter.
  • a cell or organ fibrosis control agent comprising any one of the following nucleic acids (a) to (h) as an active ingredient.
  • Nucleic acid comprising a base sequence represented by any of SEQ ID NOs: 1-27, 28-594
  • b Containing a nucleic acid comprising a base sequence represented by any of SEQ ID NOs: 1-27, 28-594
  • a nucleic acid consisting of a base sequence having a nucleotide sequence of 90% or more
  • c a sequence represented by any one of SEQ ID NOs: 1 to 27 and 28 to 594
  • e a base represented by any one of SEQ ID NOs: 1 to 27 and 28
  • a cell or organ fibrosis control agent comprising, as an active ingredient, a nucleic acid having a base sequence complementary to the base sequence of the nucleic acid described in [1].
  • a cell or organ fibrosis control agent comprising a vector that expresses the nucleic acid according to any one of [1] to [3] as an active ingredient.
  • a cell or organ fibrosis control agent comprising, as an active ingredient, a substance that suppresses the expression of the gene having the target base sequence of the nucleic acid according to [1].
  • a cell or organ fibrosis control agent comprising as an active ingredient a substance that promotes expression of a gene having the target base sequence of the nucleic acid according to [1].
  • [7] The cell or organ fibrosis regulator according to [5] or [6] above, wherein the substance that suppresses or promotes expression is a nucleic acid.
  • a cell or organ fibrosis control agent comprising the vector expressing the nucleic acid according to [7] as an active ingredient.
  • the nucleic acid according to any one of [1] to [3] above, the vector according to [4] above, or the substance according to any of [5] to [8] above as an active ingredient A therapeutic or diagnostic agent for diseases caused by fibrosis of cells or organs.
  • [11] A disease caused by fibrosis of a cell or an organ containing as an active ingredient a reagent for detecting the expression level of the nucleic acid according to [1], a mutation of the nucleic acid, or a mutation of a genome encoding the nucleic acid Diagnostics.
  • a method for treating a disease caused by fibrosis of a cell or organ characterized by comprising: [15] Diagnosis of a disease caused by fibrosis of a cell or organ, wherein the expression level of the nucleic acid according to [1], a mutation of the nucleic acid, or a mutation of a genome encoding the nucleic acid is detected Method.
  • nucleic acid according to any one of [1] to [3] above, the vector according to [4] above, or the above [for manufacturing a therapeutic agent for a disease caused by fibrosis of a cell or organ Use of the substance according to any one of [5] to [8].
  • [20] Diseases caused by fibrosis of cells or organs are acute renal failure, glomerulonephritis, vasculitis, diabetic nephropathy, hypertensive nephrosclerosis, HIV nephropathy, IgA nephropathy, lupus nephritis, stroma.
  • An agent for controlling expression of a target gene of a nucleic acid which is an active ingredient of a fibrosis regulator for cells or organs, containing the nucleic acid according to any one of [1] to [3] as an active ingredient.
  • a nucleic acid target gene expression control agent which is an active ingredient of a cell or organ fibrosis control agent, comprising the vector according to [4] as an active ingredient.
  • a method for controlling fibrosis of a cell or organ comprising using the nucleic acid according to any one of [1] to [3] above.
  • a method for controlling fibrosis of a cell or organ characterized by using the vector according to [4] above.
  • a method for controlling fibrosis of a cell or organ comprising using a substance that suppresses or promotes the expression of the target gene of the nucleic acid according to [1].
  • [26] The method for controlling fibrosis of a cell or organ according to the above [25], wherein the substance that suppresses or promotes expression is a nucleic acid.
  • [30] A method for controlling expression of a target gene of a nucleic acid, which is an active ingredient of a fibrosis control agent for cells or organs, using the vector according to [4] above.
  • [31] A screening method for a cell or organ fibrosis regulator using as an index the promotion or suppression of the expression or function of the nucleic acid according to [1].
  • a fibrosis inhibitor or fibrosis promoter for cells or organs a diagnostic or therapeutic agent for diseases caused by abnormal extracellular matrix production of cells or EMT, and an expression inhibitor for target genes of nucleic acids such as microRNA
  • an expression promoter, a method for suppressing cell fibrosis, or a method for promoting fibrosis can be provided.
  • FIG. 1 shows the results of analysis of collagen-I gene expression by real-time RT-PCR.
  • the expression of Collagen I in the liver after administration of control RNA, miR-30b, miR-486, let-7i is shown as a relative ratio to the control.
  • FIG. 2 shows the results of analysis of TGF- ⁇ gene expression by real-time RT-PCR.
  • the expression of TGF- ⁇ in the liver after administration of control microRNA, miR-30b, miR-486, let-7i is shown as a relative ratio to the control.
  • the nucleic acid used in the present invention may be any molecule as long as nucleotides and molecules having functions equivalent to the nucleotides are polymerized, such as RNA that is a ribonucleotide polymer, DNA that is a deoxyribonucleotide polymer. , A polymer in which ribonucleotides and deoxyribonucleotides are mixed, and a nucleotide polymer containing a nucleotide analog, and further a nucleotide polymer containing a nucleic acid derivative.
  • the nucleic acid in the present invention may be a single-stranded nucleic acid or a double-stranded nucleic acid.
  • the double-stranded nucleic acid also includes a double-stranded nucleic acid in which one strand is hybridized under stringent conditions to the other strand.
  • nucleotide analogues are used to improve nuclease resistance, to stabilize, to increase affinity with complementary strand nucleic acids, to increase cell permeability, or to be visualized as compared to RNA or DNA.
  • any molecule may be used as long as it is a molecule obtained by modifying ribonucleotides, deoxyribonucleotides, RNA, or DNA. Examples thereof include sugar moiety-modified nucleotide analogs and phosphodiester bond-modified nucleotide analogs.
  • the sugar moiety-modified nucleotide analog may be any one obtained by adding or substituting any chemical structural substance to a part or all of the chemical structure of the sugar of the nucleotide.
  • any chemical structural substance for example, 2'-O-methyl Nucleotide analogues substituted with ribose, nucleotide analogues substituted with 2'-O-propylribose, nucleotide analogues substituted with 2'-methoxyethoxyribose, substituted with 2'-O-methoxyethylribose Nucleotide analogues, nucleotide analogues substituted with 2'-O- [2- (guanidinium) ethyl] ribose, nucleotide analogues substituted with 2'-O-fluororibose, introducing a bridging structure into the sugar moiety Bridged Nucleic Acid (BNA) having two circular structures, more specifically,
  • the phosphodiester bond-modified nucleotide analog may be any one obtained by adding or substituting an arbitrary chemical substance to a part or all of the chemical structure of a phosphodiester bond of a nucleotide.
  • Examples include nucleotide analogues substituted with thioate linkages, nucleotide analogues substituted with N3'-P5 'phosphoramidate linkages [Cell engineering, 16 , 1463-1473 (1997)] [RNAi method And Antisense, Kodansha (2005)].
  • nucleic acid derivative in order to improve nuclease resistance, to stabilize, to increase affinity with a complementary strand nucleic acid, to increase cell permeability or to be visualized as compared with a nucleic acid, a different chemical is used. Any molecule can be used as long as it is a molecule to which a substance is added, for example, 5′-polyamine addition derivative, cholesterol addition derivative, steroid addition derivative, bile acid addition derivative, vitamin addition derivative, Cy5 addition derivative, Cy3 addition derivative, 6-FAM Examples include addition derivatives, biotin addition derivatives, and the like.
  • nucleic acid examples include nucleic acids represented by the following (a) to (k).
  • Nucleic acid comprising a base sequence represented by any of SEQ ID NOs: 1 to 594 (b) Nucleic acid comprising 17 to 28 bases comprising a nucleic acid comprising a base sequence represented by any of SEQ ID NOs: 1 to 594 (C) a nucleic acid comprising a base sequence represented by any one of SEQ ID NOs: 1 to 594 and having a nucleotide sequence having 90% or more identity (d) comprising a base sequence represented by any of SEQ ID NOs: 1 to 594 Nucleic acid that hybridizes with a complementary strand of nucleic acid under stringent conditions (e) A nucleic acid comprising the second to eighth base sequences of the base sequence represented by any one of SEQ ID NOs: 1 to 594 (f) (a) to ( a double-stranded nucleic acid comprising the nucleic acid of e) and a nucleic acid
  • a single-stranded nucleic acid or a nucleic acid containing the single-stranded nucleic acid (i) a nucleic acid consisting of a base sequence represented by any of SEQ ID NOs: 595 to 1281 (j) represented by any of SEQ ID NOs: 595 to 1281
  • a nucleic acid comprising a nucleotide sequence having 90% or more identity to the nucleotide sequence (k) a nucleic acid that hybridizes under stringent conditions with a complementary strand of a nucleic acid comprising the nucleotide sequence represented by any of SEQ ID NOs: 595 to 1281 .
  • microRNA refers to single-stranded RNA having a length of 17 to 28 bases.
  • the surrounding genomic sequence containing the microRNA sequence has a sequence that can form a hairpin structure, and the microRNA can be excised from either strand of the hairpin.
  • MicroRNAs complementarily bind to their target mRNA and suppress mRNA translation, or promote post-transcriptional control of gene expression by promoting mRNA degradation.
  • microRNA examples include human microRNA having a base sequence represented by any of SEQ ID NOs: 1 to 27. Furthermore, as a microRNA having the same function as the human microRNA consisting of the base sequence represented by any of SEQ ID NOs: 1-27, it is represented by any of SEQ ID NOs: 28-486, which is an ortholog of the human microRNA. A nucleic acid having a base sequence can be mentioned. As a specific example, the ortholog of the human microRNA of SEQ ID NO: 1 includes those consisting of the base sequences represented by SEQ ID NOs: 28 to 33 and 37 to 39. Table 1 shows a correspondence table between microRNAs having the base sequences represented by SEQ ID NOs: 1 to 27 and their orthologs.
  • hsa Homo sapiens, humans; mmu, Mus musculus, mice; rno, Rattus norvegicus, rats; cgr, Cricetulus griseus, Chinese hamsters; age, Ateles geoffroyi, red spider monkeys; Mnea catamarin; mml, Macaca mulatta, rhesus monkey; mne, Macaca nemestrina, pigtail monkey; pbi, Pygathrix bieti, black goldfish; ggo, Gorilla gorilla, gorilla; ppa, Pan paniscus, bonobo; ptr, Pan trogopy; Ssy, Symphalangus syndactylus, octopus gibbon; lca, Lemur catta, ring-tailed lemur; oan, Ornithorhynchus anatinus
  • microRNA As a mechanism by which microRNA suppresses translation of mRNA of its target gene, mRNA having a base sequence complementary to the 2-8th base sequence on the 5 'end side of microRNA is recognized as a microRNA target gene. [Current Biology, 15 , R458-R460 (2005)]. By this mechanism, the expression of the mRNA is suppressed by the microRNA. Accordingly, microRNAs having the same base sequence on the 2nd to 8th positions on the 5 ′ end side have the same function by suppressing the expression of the same mRNA.
  • a base represented by any one of SEQ ID NOs: 487 to 594 as a microRNA having the same base sequence at the 5 'end side from the microRNA having the base sequence represented by any one of SEQ ID NOs: 1 to 27 A nucleic acid consisting of a sequence can be mentioned.
  • the microRNA for the microRNA consisting of the base sequence represented by SEQ ID NO: 1, microRNA consisting of the base sequence represented by SEQ ID NOs: 487 and 488 can be mentioned.
  • Artificial microRNA is also included in microRNA.
  • Table 2 shows a correspondence table between the microRNAs having the base sequences represented by SEQ ID NOs: 1 to 27 and the microRNAs having the same base sequence at the second to eighth positions on the 5 ′ end. MicroRNAs having a common seed sequence are considered to have the same function because their target base sequences are considered identical.
  • a microRNA precursor is also preferably used as the nucleic acid.
  • the microRNA precursor is a nucleic acid having a length of about 50 to about 200 bases, more preferably about 70 to about 100 bases including the above-mentioned nucleic acid, and can form a hairpin structure.
  • MicroRNA is produced from a microRNA precursor through processing by a protein called Dicer.
  • microRNA precursor examples include a nucleic acid having a base sequence represented by SEQ ID NO: 595 for human microRNA of SEQ ID NO: 1.
  • a nucleic acid having a base sequence represented by any of SEQ ID NOs: 2 to 594 a nucleic acid having a base sequence represented by any of SEQ ID NOs: 596 to 1281 can be exemplified.
  • Table 3 shows the correspondence between the microRNA and the microRNA precursor in the present invention.
  • the microRNA precursor includes an artificial microRNA precursor.
  • a nucleic acid having 90% or more identity with the nucleotide sequence represented by any of SEQ ID NOs: 1-1811 is BLAST [J. Mol. Biol., 215 , 403 (1990)] or FASTA [ Methods in Enzymology, 183 , 63 (1990)], etc., and at least 90% or more, preferably 93% of the nucleic acid consisting of the base sequence represented by any of SEQ ID NOs: 1-1811 It means that the nucleic acid has the identity of 95% or more, more preferably 96% or more, particularly preferably 97% or more, and most preferably 98% or more.
  • the stringent conditions in the above are, for example, 7.5 mL, 1 M Na 2 HPO 4 (pH 7.2) 0.6 mL, 10% SDS 21 mL, 50x Denhardt's solution 0.6 mL, 10 Add the other strand labeled with 32 P-ATP to the Hybridization buffer consisting of 0.3 mL of mg / mL sonicated salmon sperm DNA, react at 50 ° C overnight, then react at 50 ° C for 10 minutes, 5x SSC / 5% SDS solution And then washed with 1 ⁇ SSC / 1% SDS solution at 50 ° C. for 10 minutes, and then the membrane is taken out and exposed to an X-ray film to detect the signal.
  • Those skilled in the art can appropriately select the hybridization conditions that give the same stringency.
  • any method for detecting the expression of a nucleic acid such as microRNA using a nucleic acid can be used as long as it can detect the presence of a nucleic acid such as microRNA or a microRNA precursor in a sample.
  • a nucleic acid such as microRNA or a microRNA precursor in a sample.
  • any method can be used as long as it can detect the presence of a nucleic acid such as microRNA or a microRNA precursor in a sample.
  • any method can be used as long as it can detect a mutation in the base sequence of a nucleic acid such as microRNA or a microRNA precursor in a sample.
  • a method for detecting a heteroduplex formed by hybridization of a nucleic acid having a non-mutated base sequence and a nucleic acid having a mutant base sequence, or by directly sequencing a base sequence derived from a specimen A method for detecting the presence or absence can be given.
  • the vector expressing nucleic acid may be any vector as long as it is designed to biosynthesize nucleic acid such as microRNA by being introduced into a cell and transcribed.
  • vectors capable of expressing nucleic acids such as microRNA in cells include pCDNA6.2-GW / miR (Invitrogen), pSilencer4.1-CMV (Ambion), pSINsi-hH1 DNA (Takara Bio), pSINsi-hU6UDNA (Takara Bio), pENTR / U6 (Invitrogen), microRNA Archive (Takara Bio), pMIRRNA1 (System Bioscience), etc. it can.
  • a target gene As a method for suppressing the expression of a gene having a target base sequence of a nucleic acid such as microRNA (hereinafter referred to as a target gene), the activity of suppressing the expression of mRNA having a target base sequence of a nucleic acid such as microRNA is utilized. Any method may be used as long as it suppresses the expression of a gene having the target base sequence.
  • suppression of expression here includes a case where the translation of mRNA is suppressed, and a case where the amount of protein translated from mRNA is reduced by cleaving or decomposing mRNA.
  • Specific examples of substances that suppress the expression of mRNA having the target base sequence include nucleic acids such as siRNA and antisense oligonucleotides.
  • the siRNA can be prepared based on the continuous sequence information of the mRNA [Genes Dev., 13 , 3191 (1999)].
  • the number of residues of the base constituting one strand of siRNA is preferably 17 to 30 residues, more preferably 18 to 25 residues, still more preferably 19 to 23 residues.
  • the microRNA is a single-stranded RNA having a length of 17 to 28 bases containing a sequence complementary to a continuous 7 base sequence existing in the 3 ′ untranslated region of the mRNA of the target gene as the second to eighth base sequences. Some artificial microRNAs are also included. When the sequence including the sequence and extending it back and forth forms a hairpin structure, and the microRNA sequence is RNA that can be excised from any one strand of the hairpin structure in the cell by the microRNA biosynthetic pathway, The extended sequence is called an artificial microRNA precursor. Artificial microRNAs and artificial microRNA precursors can be designed using the method as described above using a gene whose expression is to be suppressed as a target gene.
  • the target base sequence of nucleic acid such as microRNA is a base sequence consisting of several bases recognized by nucleic acid such as microRNA in the present invention, and the expression of mRNA having the base sequence is such as microRNA in the present invention.
  • the base sequence complementary to the 2-8th base sequence on the 5 ′ end side of the microRNA is that translation of mRNA having the base sequence is suppressed by the microRNA [Current Biology, 15 , R458-R460]. (2005)], a base sequence complementary to the second to eighth base sequences on the 5 ′ end side of nucleic acids such as microRNA in the present invention can be mentioned as the target base sequence.
  • an mRNA containing a sequence that perfectly matches the 3 'UTR base sequence group of human mRNAs by preparing a target sequence complementary to the 2-8th base sequence on the 5' end side of the microRNA. Can be determined by selecting by a method such as a character string search.
  • the 3'UTR base sequence group of human mRNA should be prepared using the genome sequence and gene position information that can be obtained from "UCSC Human Genome Browser Gateway (http://genome.ucsc.edu/cgi-bin/hgGateway)". Can do.
  • a method for expressing a nucleic acid such as microRNA in a cell includes a method using a nucleic acid that expresses a gene encoding the microRNA when introduced into the cell.
  • the nucleic acid in addition to DNA, RNA, or nucleotide analogues, these chimeric molecules or derivatives of the nucleic acids can also be used.
  • the nucleic acid can be designed in the same manner as Pre-miRTMmimiRNA Precursor Molecules (Ambion) or miRIDIAN microRNA Mimics (GE Healthcare) to express nucleic acids such as microRNA in cells. it can.
  • any method may be used as long as microRNA can finally be produced in the cell.
  • RNA in addition to introducing single-stranded RNA as a microRNA precursor, (2) There is a method for introducing microRNA itself and RNA consisting of complementary strands of microRNA and 100% -matched double-stranded RNA, and (3) double-stranded RNA assuming the state after microRNA is cleaved into Dicer.
  • Examples of products using such a method include miCENTURY OX Precursor (manufactured by B-Bridge), miCENTURY OX siMature (manufactured by B-Bridge), and miCENTURY OX miNatural (manufactured by B-Bridge).
  • the method for synthesizing the nucleic acid used in the present invention is not particularly limited, and it can be produced by a method using a known chemical synthesis, an enzymatic transcription method or the like.
  • methods using known chemical synthesis include phosphoramidite method, phosphorothioate method, phosphotriester method, etc.
  • synthesis with ABI3900 high-throughput nucleic acid synthesizer can do.
  • the enzymatic transcription method include transcription using a typical phage RNA polymerase, for example, T7, T3, or SP6 RNA polymerase, using a plasmid or DNA having the target base sequence as a template.
  • Examples of a method for screening for a substance that promotes or suppresses the expression or function of the nucleic acid using the nucleic acid used in the present invention include, for example, introducing a vector that expresses the nucleic acid into a cell, and expressing an mRNA having the target base sequence. Alternatively, a method of screening for a substance that promotes or suppresses the function can be mentioned.
  • the pharmaceutical comprising the nucleic acid used in the present invention as an active ingredient can be used for diagnosis or treatment of diseases caused by fibrosis of cells or organs, tissue hyperplasia, or the like.
  • the nucleic acid can also be used as a fibrosis control agent for cells or organs.
  • Cell or organ fibrosis as used herein refers to a state in which extracellular matrix production is abnormally increased in the living body or a state in which epithelial-mesenchymal transition (EMT) occurs.
  • EMT epithelial-mesenchymal transition
  • An agent refers to an inhibitor or an accelerator.
  • “fibrosis of cells or organs” is not limited to fibrosis of only one of cells or organs, but includes cases where both cells and organs are fibrotic.
  • diseases caused by cell or organ fibrosis or tissue hyperplasia include, for example, fibrosis associated with damage to fibrous tissue.
  • the fibrous tissue is not particularly limited as long as it has a connective tissue, for example, kidney, lung, liver, heart, pancreas, spleen, stomach, spinal cord, pituitary gland, gonad, thyroid, gallbladder, Bone marrow, adrenal gland, skin, digestive tract (eg, large intestine, small intestine), brain, brain parts (eg, olfactory bulb, amygdala, basal sphere, hippocampus, thalamus, hypothalamus, cerebral cortex, medulla, cerebellum), bladder , Testis, ovary, placenta, uterus, bone, joint, skin, blood vessel, adipose tissue, skeletal muscle and the like.
  • a connective tissue for example, kidney, lung, liver, heart, pancreas, spleen, stomach, spinal cord
  • the disease include, but are not limited to, acute renal failure, glomerulonephritis, vasculitis, diabetic nephropathy, hypertensive nephrosclerosis, HIV nephropathy, IgA nephropathy, lupus nephritis, interstitial Nephritis, fibrosis associated with renal disorders such as obstructed kidney due to ureteral obstruction, pulmonary fibrosis, cirrhosis, arteriosclerosis, scleroderma, coronary restenosis after percutaneous transluminal coronary vasodilation (PTCA), between Examples include interstitial myocarditis, interstitial cystitis, skin scarring after burn injury, and fibrosis associated with poisoning.
  • PTCA percutaneous transluminal coronary vasodilation
  • RNA RNA
  • Identification of microRNA Whether a small RNA sequence is microRNA is determined by RNA (RNA) ), 9 , 277-279 (2003).
  • RNA RNA
  • RNA predicted to be transcribed from the genomic sequence Predict secondary structure.
  • Genomic sequences are publicly available and are available, for example, from UCSC Genome Bioinformatics (http://genome.ucsc.edu/).
  • RNAfold Nucleic Acids Research, 31 , 3429-3431 (2003)
  • Mfold Nucleic Acids Research, 31 , 3406-3415 (2003)
  • miRBase a database that maps miRBase to existing microRNAs.
  • low molecular weight RNA can be obtained by 15% polyacrylamide gel electrophoresis in accordance with the method described in Jeans & Development (Genes & Development), 15 , 188-200 (2000). The method of separating is mentioned. From this, 5'-terminal dephosphorylation, 3'-adapter ligation, phosphorylation, 5'-adapter ligation, reverse transcription, PCR amplification, concatamerization, and ligation to vector are sequentially cloned, and the clone is cloned. Can be determined.
  • RNA can be cloned and the base sequence of the clone can be determined.
  • RNA Cloning Kit manufactured by Takara Bio Inc.
  • 1-3 Method for detecting expression level of nucleic acid such as microRNA
  • methods for detecting the expression level of nucleic acid such as microRNA and its precursor include (1) Northern hybridization and (2) dot blot high. Hybridization, (3) in situ hybridization, (4) quantitative PCR, (5) differential hybridization, (6) microarray, (7) ribonuclease protection assay.
  • Northern blotting is a method in which sample-derived RNA is separated by gel electrophoresis, then transferred to a support such as a nylon filter, a probe labeled appropriately based on the base sequence of the nucleic acid is prepared, and hybridization and washing are performed.
  • this is a method for detecting a band specifically bound to a nucleic acid. Specifically, for example, it can be performed according to the method described in Science, 294 , 853-858 (2001).
  • the labeled probe is a base sequence of a nucleic acid used in the present invention, for example, a radioisotope, biotin, digoxigenin, a fluorescent group, a chemiluminescent group, etc. by a method such as nick translation, random priming or phosphorylation at the 5 ′ end. It can be prepared by incorporating it into DNA or RNA having a complementary sequence to LNA or LNA. Since the binding amount of the labeled probe reflects the expression level of the nucleic acid, the expression level of the nucleic acid can be quantified by quantifying the amount of bound labeled probe. Electrophoresis, transfer to membrane, probe preparation, hybridization, and nucleic acid detection can be performed by the method described in Molecular Cloning 3rd Edition [Cold Spring Harbor Press, (2001) Cold Spring Harbor, NY] it can.
  • RNA extracted from tissues and cells is spot-fixed on a membrane in a dotted manner, and then hybridized with a labeled polynucleotide that serves as a probe to detect RNA that specifically hybridizes with the probe. It is a method to do.
  • the probe the same probe as in Northern hybridization can be used. Preparation of RNA, RNA spot, hybridization, and detection of RNA can be performed by the methods described in Molecular Cloning 3rd edition.
  • In situ hybridization uses a paraffin or cryostat section of tissue obtained from a living body or immobilized cells as a specimen, performs hybridization and washing steps with a labeled probe, and observes the tissue and nucleic acid of a nucleic acid by microscopic observation. It is a method for examining distribution and localization in cells [Methods in Enzymology, 254 , 419 (1995)].
  • the probe the same probe as in Northern hybridization can be used. Specifically, microRNA can be detected according to the method described in Nature Method, 3 , 27 (2006).
  • cDNA synthesized from a sample-derived RNA using a reverse transcription primer and a reverse transcriptase (hereinafter, the cDNA is referred to as a sample-derived cDNA) is used for measurement.
  • a reverse transcription primer used for cDNA synthesis a random primer or a specific RT primer can be used.
  • the specific RT primer refers to a primer having a sequence complementary to a nucleic acid and a base sequence corresponding to the surrounding genomic sequence.
  • a template-specific design designed from a nucleotide sequence corresponding to a nucleic acid such as microRNA or a microRNA precursor and its surrounding genomic sequence, or a nucleotide sequence corresponding to a reverse transcription primer PCR is performed using a typical primer, a cDNA fragment containing the nucleic acid is amplified, and the amount of the nucleic acid contained in the sample-derived RNA is detected from the number of cycles until a certain amount is reached.
  • an appropriate region corresponding to the nucleic acid and the surrounding genomic sequence is selected, and consists of a sequence of 15 to 40 residues, preferably 20 to 30 residues at the 5 ′ end of the base sequence of the region.
  • a set of DNA or LNA consisting of DNA or LNA and a sequence complementary to 15 to 40 residues, preferably 20 to 30 residues at the 3 ′ end can be used. Specifically, it can be performed according to the method described in Nucleic Acids Research, 32 , e43 (2004).
  • a specific RT primer having a stem-loop structure can also be used as a reverse transcription primer for cDNA synthesis. Specifically, the method described in Nucleic Acid Research, 33, e179 ( 2005) or can be performed using the TaqMan MicroRNA Assays (Applied Biosystems).
  • a reverse transcription reaction can also be performed by adding a polyA sequence to a sample-derived RNA with polyA polymerase and using a base sequence containing an oligo dT sequence as a primer for reverse transcription. .
  • it can be performed using miScript System (Qiagen), QuantiMir RT Kit (System Biosciences), PrimeScript 1st strand cDNA Synthesis (Takara Bio).
  • miScript System Qiagen
  • QuantiMir RT Kit System Biosciences
  • PrimeScript 1st strand cDNA Synthesis Takara Bio
  • Examples of the method based on such hybridization include a method using differential hybridization [Trends Genet., 7 , 314 (1991)] and a microarray [Genome Res., 6 , 639 (1996)].
  • the difference in the amount of nucleic acid between the control sample and the target sample can be accurately detected by immobilizing an internal control such as a base sequence corresponding to U6 RNA on a filter or substrate.
  • labeled cDNA synthesis using differently labeled dNTPs mixturetures of dATP, dGTP, dCTP, and dTTP
  • RNA derived from the control sample and the target sample and two filters on one filter or one substrate.
  • nucleic acid quantification can be performed by simultaneously hybridizing labeled cDNA. Furthermore, the nucleic acid can be quantified by directly labeling and hybridizing RNA derived from the control sample and / or the target sample. For example, using a microarray described in Proc. Natl. Acad. Sci. USA, 101 , 9740-9744 (2004), Nucleic Acid Research, 32 , e188 (2004), RNA, 13 , 151-159 (2007), etc. MicroRNA can be detected. Specifically, it can be detected or quantified in the same manner as mirVana miRNA Bioarray (Ambion) and miRNA microarray kit (Agilent Technology).
  • a promoter sequence such as T7 promoter and SP6 promoter is bound to the 3 ′ end of the nucleotide sequence corresponding to the nucleic acid or its surrounding genomic sequence, and labeled NTP (mixture of ATP, GTP, CTP, UTP) and Labeled antisense RNA is synthesized by an in vitro transcription system using RNA polymerase.
  • the labeled antisense RNA is bound to the sample-derived RNA to form an RNA-RNA hybrid, and then digested with ribonuclease A that degrades only single-stranded RNA.
  • RNA fragments protected from digestion by forming RNA-RNA hybrids are detected or quantified as nucleic acids. Specifically, it can be detected or quantified using mirVana miRNA Detection Kit (Ambion).
  • RNAs or microRNA precursors that are expressed in cells or fibrotic tissues with increased fibrosis, or whose expression is increased or decreased compared to normal tissues, etc.
  • DNA that is a polymer of deoxyribonucleotides
  • the base sequence of DNA can be determined based on the base sequence of microRNA identified in 1 above.
  • the base sequence of DNA corresponding to the base sequence of RNA can be uniquely determined by replacing U (uracil) contained in the RNA sequence with T (thymine).
  • a polymer in which ribonucleotides and deoxyribonucleotides are mixed, a polymer containing nucleotide analogues, and a nucleic acid derivative can be synthesized in the same manner.
  • the method for synthesizing the nucleic acid is not particularly limited, and the nucleic acid can be produced by a method using known chemical synthesis or an enzymatic transcription method.
  • methods using known chemical synthesis include phosphoramidite method, phosphorothioate method, phosphotriester method, etc.
  • synthesis with ABI3900 high-throughput nucleic acid synthesizer can do.
  • the enzymatic transcription method include a transcription method using a typical phage RNA polymerase such as T7, T3, or SP6 RNA polymerase using a plasmid or DNA having the target base sequence as a template.
  • Method for detecting the function of a nucleic acid such as microRNA or microRNA precursor As a method for detecting the function of a nucleic acid such as microRNA, there is a method for detecting whether or not the translation of mRNA having a target base sequence is suppressed. be able to.
  • microRNA suppresses translation of mRNA containing the target base sequence in the 3 ′ terminal untranslated region (3′UTR) [Current Biology, 15 , R458-R460 (2005)]. Therefore, a DNA in which the target base sequence for the single-stranded RNA to be measured is inserted into the 3′UTR of an appropriate reporter gene expression vector is prepared, introduced into a host cell suitable for the expression vector, and single-stranded into the cell. By measuring the expression of a reporter gene when RNA is expressed, it can be detected whether or not it has a function of microRNA.
  • the reporter gene expression vector may be any vector as long as it has a promoter upstream of the reporter gene and can express the reporter gene in the host cell.
  • Any reporter gene can be used as the reporter gene, for example, firefly luciferase gene, Renilla luciferase gene, chloramphenicol acetyltransferase gene, ⁇ -glucuronidase gene, ⁇ -galactosidase gene, ⁇ -Lactamase gene, aequorin gene, green fluorescent protein gene and DsRed fluorescent gene can be used.
  • Reporter gene expression vectors having such properties include, for example, psiCHECK-1 (Promega), psiCHECK-2 (Promega), pGL3-Control (Promega), pGL4 (Promega), pRNAi-GL ( (Takara Bio), pCMV-DsRed-Express (CLONTECH), pMIR-REPORT® System (Ambion). Single-stranded RNA can be expressed by the method described in 6 below.
  • the function of single-stranded RNA as a microRNA can be specifically detected as follows. First, host cells are cultured in a multi-well plate or the like to express a reporter gene expression vector having a target sequence and single-stranded RNA. Then, the reporter activity is measured, and the function of the single-stranded RNA as a microRNA is detected by measuring the reporter activity when the single-stranded RNA is expressed compared to the case where the single-stranded RNA is not expressed. can do.
  • Method for detecting mutations in nucleic acids such as microRNA and microRNA precursors As a method for detecting mutations in nucleic acids such as microRNAs and microRNA precursors, heterogeneous nucleic acids formed by hybridization of normal and mutant nucleic acids A method for detecting this strand can be used.
  • Methods for detecting heteroduplex include (1) heteroduplex detection by polyacrylamide gel electrophoresis [Trends genet., 7 , 5 (1991)], (2) single strand conformation polymorphism analysis [Genomics, 16 , 325-332 (1993)], (3) Chemical cleavage of mismatches (CCM) [Human Genetics (1996), Tom Strachan and Andrew P. Read, BIOS Scientific Publishers Limited ], (4) Enzymatic cleavage method of mismatch [Nature Genetics, 9 , 103-104 (1996)], (5) Denaturing gel electrophoresis [Mutat. Res., 288 , 103-112 (1993)], etc. There are methods.
  • the heteroduplex detection method by polyacrylamide gel electrophoresis is performed as follows, for example. First, using a specimen-derived DNA or a specimen-derived cDNA as a template, a primer designed based on the genomic base sequence including the nucleic acid base sequence is amplified as a fragment smaller than 200 ⁇ bp. When heteroduplexes are formed, the mobility is slower than homoduplexes without mutations, and they can be detected as extra bands. If the fragment is smaller than 200 bp, most insertions, deletions and substitutions of 1 base or more can be detected. Heteroduplex analysis is preferably performed on a single gel combined with single-strand conformation analysis described below.
  • SSCP analysis single-strand conformation polymorphism analysis
  • primers derived from the base sequence of the genome including the base sequence of the nucleic acid
  • sample-derived DNA or the sample-derived cDNA as a template
  • the DNA amplified as a fragment smaller than 200 bp is denatured and electrophoresed in a native polyacrylamide gel.
  • the amplified DNA can be detected as a band by labeling the primer with an isotope or a fluorescent dye, or silver-staining the unlabeled amplification product.
  • a fragment having a mutation can be detected from the difference in mobility.
  • CCM method DNA fragments amplified with primers designed based on the base sequence of the genome including the base sequence of the nucleic acid using the sample-derived DNA or the sample-derived cDNA as a template are used as isotopes or fluorescence in the nucleic acid.
  • a labeled nucleic acid incorporating a label By hybridizing with a labeled nucleic acid incorporating a label and treating with osmium tetroxide, one strand of DNA at a position where a mismatch exists can be cleaved to detect a mutation.
  • CCM is one of the most sensitive detection methods and can be applied to specimens of kilobase length.
  • the mismatch can be cleaved enzymatically by combining RNase A with an enzyme involved in mismatch repair in cells such as T4 phage resol base and endonuclease VII.
  • DGGE method DNA fragments amplified with primers designed based on genomic base sequences, including nucleic acid base sequences, are used chemically, using specimen-derived DNA or specimen-derived cDNA as a template. Electrophoresis is performed using a gel having a denaturant concentration gradient and a temperature gradient. The amplified DNA fragment moves in the gel to a position where it is denatured into a single strand and does not move after denaturation. Since there is a difference in the movement of the amplified DNA in the gel with and without the mutation, the presence of the mutation can be detected.
  • a poly (G: C) terminal is preferably attached to each primer.
  • nucleic acid mutations can be detected by directly determining and analyzing the base sequence of the sample-derived DNA or the sample-derived cDNA.
  • nucleic acids such as microRNA and microRNA precursors
  • RNA sequences and their precursor sequences are registered in a database called miRBase at the Sanger Center in the UK.
  • Nucleic acids such as RNA precursors can be made. It can also be prepared using the microRNA sequence obtained by the method described in 1.
  • the nucleic acid can be expressed by using a vector that is biosynthesized by introduction into a cell and transcription. Specifically, based on the base sequence of the nucleic acid or the genomic base sequence containing the base sequence, a DNA fragment containing the hairpin portion is prepared and inserted downstream of the promoter of the expression vector to construct an expression plasmid. Next, the nucleic acid can be expressed by introducing the expression plasmid into a host cell suitable for the expression vector.
  • a vector that can replicate autonomously in a host cell or can be integrated into a chromosome and contains a promoter at a position where a gene containing a nucleic acid base sequence can be transcribed is used.
  • Any promoter can be used as long as it can be expressed in the host cell.
  • a promoter etc. can be mention
  • the Pol II promoter include a promoter of cytomegalovirus (human CMV) IE (immediate early) gene, an early promoter of SV40, and the like.
  • Examples of expression vectors using them include pCDNA6.2-GW / miR (Invitrogen), pSilencer® 4.1-CMV (Ambion), and the like.
  • Examples of pol III promoters include U6 RNA, H1 RNA, and tRNA gene promoters.
  • Examples of expression vectors using them include pSINsi-hH1 DNA (Takara Bio), pSINsi-hU6 DNA (Takara Bio), and pENTR / U6 (Invitrogen).
  • a gene containing a nucleic acid base sequence is inserted downstream of a promoter in a viral vector to construct a recombinant viral vector, the vector is introduced into a packaging cell to produce a recombinant virus, and the nucleic acid base sequence is determined. Genes containing can also be expressed.
  • the packaging cell may be any cell as long as it can replenish the deficient protein of the recombinant viral vector deficient in any of the genes encoding the proteins required for virus packaging, for example, from human kidney HEK293 cells, mouse fibroblast NIH3T3-derived cells, and the like can be used.
  • Proteins supplemented by packaging cells include mouse retrovirus-derived gag, pol, env, etc. for retrovirus vectors, and HIV virus-derived gag, pol, env, vpr, vpu for lentiviral vectors.
  • Vif, tat, rev, nef, etc. in the case of adenovirus vectors, proteins such as E1A and E1B derived from adenovirus, and in the case of adeno-associated virus vectors, Rep (p5, p19, p40), Vp (Cap), etc. Can be used.
  • nucleic acid used in the present invention can be directly introduced into a cell without using a vector.
  • a nucleic acid used in this method in addition to DNA, RNA, or nucleotide analogues, these chimeric molecules or derivatives of the nucleic acids can be used.
  • nucleic acids such as microRNAs and microRNA precursors can be expressed in the same manner as Pre-miRTM miRNA Precursor Molecules (Ambion) or miRIDIAN microRNA Mimics (GE Healthcare). When microRNA is expressed, any method can be used as long as microRNA can finally be produced in the cell.
  • RNA in addition to introducing single-stranded RNA as a microRNA precursor, (2) There is a method of introducing microRNA itself and RNA consisting of a complementary strand of microRNA and 100% -matched double-stranded RNA, and (3) double-stranded RNA assuming a state after microRNA is cleaved into Dicer. can give. Products that use these methods include miCENTURY OX Precursor (B-Bridge), miCENTURY OX siMature (B-Bridge), and miCENTURY OX miNatural (B-Bridge).
  • B-Bridge miCENTURY OX Precursor
  • B-Bridge miCENTURY OX siMature
  • B-Bridge miCENTURY OX miNatural
  • nucleic acids such as microRNAs and microRNA precursors are antisense technologies [Bioscience and Industry, 50 , 322 (1992), Chemistry, 46 , 681 ( 1991), Biotechnology, 9 , 358 (1992), Trends in Biotechnology, 10 , 87 (1992), Trends in Biotechnology, 10 , 152 (1992), Cell Engineering, 16 , 1463 (1997)], Triple Helix Technology [ Trends in Biotechnology, 10 , 132 (1992)], ribozyme technology [Current Opinion in Chemical Biology, 3 , 274 (1999), FEMS Microbiology Reviews, 23 , 257 (1999), Frontiers in Bioscience, 4 , D497 (1999), Chemistry & Biology, 6 , R33 (1999), Nucleic Acids Research, 26 , 5237 (1998), Trends In Biotechnology, 16 , 438 (1998)], Decoy DNA method [Nippon Rinsho-Japanese Journal of Clinical Medicine, 56
  • Antisense refers to a nucleic acid that can specifically hybridize a nucleic acid having a base sequence complementary to the base sequence of a certain target nucleic acid to suppress the expression of the target nucleic acid.
  • the nucleic acid used for antisense in addition to DNA, RNA or nucleotide analogs, these chimeric molecules or derivatives of the nucleic acids can also be used.
  • antisense can be produced and expression can be suppressed by following the method described in Nature, 432 , 226 (2004) and the like.
  • the siRNA is a short double-stranded RNA containing a base sequence of a certain target nucleic acid and can suppress the expression of the target nucleic acid by RNA interference (RNAi).
  • RNAi RNA interference
  • sequence of the siRNA the literature of the nucleotide sequence [Genes Dev., 13, 3191 (1999)] targeting can be appropriately designed based on the conditions.
  • siRNA can be prepared by synthesizing and annealing two RNAs having a sequence of 19 bases selected and a sequence obtained by adding TT to the 3 ′ end of each complementary sequence and annealing.
  • siRNA expression vector such as pSilencer 1.0-U6 (Ambion) or pSUPER (OligoEngine)
  • a vector expressing siRNA can be prepared.
  • the siRNA that suppresses a nucleic acid such as microRNA used in the present invention may be any siRNA that can suppress the activity of the nucleic acid, but each of the nucleotide sequences represented by any of SEQ ID NOs: 1 to 594 SiRNA designed from continuous sequence information after the 9th base is preferred.
  • the number of residues of the base constituting one strand of siRNA is preferably 17 to 30 residues, more preferably 18 to 25 residues, still more preferably 19 to 23 residues.
  • MicroRNA expressed in fibrotic cells using antisense or siRNA specific to nucleic acids such as microRNA and microRNA precursors expressed in fibrotic cells or tissues (hereinafter also referred to as “fibrotic cells”) And the expression of microRNA precursors can be suppressed.
  • fibrotic cells fibrotic cells
  • antisense or siRNA specific to nucleic acids such as microRNA and microRNA precursors expressed in fibrotic cells or tissues
  • the expression of microRNA precursors can be suppressed.
  • the activity of the microRNA is suppressed and the action of the microRNA or microRNA precursor in fibrotic cells is controlled. can do.
  • fibrotic cells can be obtained by administering to the patient an antisense oligonucleotide or siRNA specific to the microRNA or its precursor.
  • the disease which develops by the said expression abnormality can be treated. That is, an antisense oligonucleotide or siRNA specific to the microRNA or a precursor thereof is useful as a therapeutic agent for diseases caused by abnormal production of extracellular matrix, that is, fibrosis.
  • the antisense oligonucleotide or siRNA specific to a nucleic acid such as microRNA or a precursor thereof
  • the antisense oligonucleotide or siRNA alone or the nucleic acid encoding them is a retroviral vector
  • an appropriate vector such as an adenovirus vector or an adeno-associated virus vector
  • nucleic acid such as microRNA is used for expression of mRNA having target base sequence. Any method may be used as long as it uses the inhibitory activity. For example, by expressing a nucleic acid such as microRNA and increasing the amount of nucleic acid such as microRNA in the cell, it is possible to suppress the translation of mRNA having the target sequence and to suppress the expression of the gene. .
  • the nucleic acid can be expressed by the method described in 5 above. Examples of the mRNA having the target base sequence of the nucleic acid consisting of the base sequence represented by any of SEQ ID NOs: 1 to 594 can include the gene groups shown in Table 4 above, for example.
  • the function of the target gene can be suppressed using siRNA for the target gene shown in Table 4.
  • Method for screening a substance that promotes or suppresses expression or function of nucleic acid using nucleic acid such as microRNA or microRNA precursor Using nucleic acid to promote expression or function of nucleic acid such as microRNA or its precursor Substances to be suppressed can be screened. For example, by selecting a base sequence to be screened from the base sequence of a nucleic acid and utilizing a cell that expresses a nucleic acid having the base sequence, the expression or function of the selected microRNA or its precursor is promoted or Substances to be suppressed can be screened.
  • a vector expressing a nucleic acid having the base sequence may be an animal cell, A transformed cell obtained by introduction into a host cell such as yeast, a cell into which a nucleic acid having the base sequence is directly introduced without using a vector, and the like can also be used.
  • Specific screening methods include methods that use changes in the expression level of nucleic acids such as microRNAs or their precursors to be screened as indicators, as well as mRNAs that have nucleic acid target sequences such as microRNAs, and encoded by them.
  • a method using the change in the expression level of the gene product as an index can be mentioned.
  • (A) Screening method using as an index a change in the expression level of a nucleic acid such as a microRNA or a precursor thereof as a target for screening The test substance is contacted with a cell expressing the nucleic acid, and the expression level of the selected nucleic acid is determined.
  • a substance that promotes or suppresses nucleic acids such as expression of microRNA and its precursor is obtained.
  • the expression level of the nucleic acid can be detected by the method described in 3 above.
  • (B) Screening method using as an index the change in the expression level of mRNA having a nucleic acid target sequence such as microRNA to be screened and the gene product encoded by it Contact test cells with cells expressing the mRNA
  • a substance that promotes or suppresses the expression or function of nucleic acids such as microRNA and its precursor is obtained using changes in the expression level of mRNA having the target sequence of the selected nucleic acid and the gene product encoded thereby as an index.
  • a DNA in which the target sequence of a nucleic acid such as microRNA is inserted into the 3′UTR of an appropriate reporter gene expression vector is prepared, introduced into a host cell suitable for the expression vector, and a test substance is contacted with the cell, Using a change in the expression level of the reporter gene as an indicator, a substance that promotes or suppresses the expression or function of nucleic acids such as microRNA and its precursor is obtained.
  • mRNA having a nucleic acid target sequence such as a microRNA comprising a base sequence represented by any of SEQ ID NOs: 1 to 594 include: Examples of the gene groups shown in Table 4 above can be given.
  • Cell fibrosis inhibitor or fibrosis promoter using nucleic acid such as microRNA or microRNA precursor Nucleic acid such as microRNA or microRNA precursor, and nucleic acid having a base sequence complementary to the base sequence are: By controlling the expression of a gene having a target sequence, it can be used as a cell fibrosis inhibitor or fibrosis promoter.
  • Examples of the organ or cell fibrosis inhibitor include the following nucleic acids mentioned in (a) to (h).
  • a nucleic acid having a nucleotide sequence of 17 to 28 nucleotides (c) having 90% or more identity with the nucleotide sequence represented by any of SEQ ID NOs: 1 to 23, 28 to 411, and 487 to 589
  • SEQ ID Nos. 595 to 618, 624 to 1073, and 1156 to 1277 Nucleic acid comprising a base sequence represented by any of the above (g) A nucleic acid comprising a base sequence represented by any one of SEQ ID NOs: 595 to 618, 624 to 1073, and 1156 to 1277 and having a nucleotide sequence of 90% or more (H) a nucleic acid that hybridizes under stringent conditions with a complementary strand of a nucleic acid comprising the base sequence represented by any of SEQ ID NOs: 619 to 623, 1074 to 1155, and 1278 to 1281.
  • organ or cell fibrosis promoters include nucleic acids listed in (i) to (p) below.
  • Nucleic acid consisting of a base sequence (l) Nucleic acid (m) sequence that hybridizes under stringent conditions with a complementary strand of a nucleic acid consisting of a base sequence represented by any one of SEQ ID NOs: 1 to 23, 28 to 411, and 487 to 589 Nucleic acids containing the second to eighth base sequences of the base sequences represented by any of Nos.
  • SEQ ID Nos. 619 to 623, 1074 to 1155, 12 Nucleic acid consisting of a base sequence represented by any one of 8 to 1281 (o) A base having 90% or more identity with the base sequence represented by any one of SEQ ID NOs: 619 to 623, 1074 to 1155, 1278 to 1281 Nucleic acid consisting of sequence (p) A nucleic acid that hybridizes under stringent conditions with a complementary strand of nucleic acid consisting of a base sequence represented by any of SEQ ID NOs: 595 to 618, 624 to 1073, and 1156 to 1277.
  • the nucleic acid microRNA or a microRNA precursor is preferably used as the nucleic acid.
  • Examples of the fibrosis promoter for cells or organs include nucleic acids having a base sequence complementary to the base sequences of the nucleic acids described in (a) to (h) above. Examples thereof include nucleic acids having a base sequence complementary to the base sequences of the nucleic acids described in (i) to (p) above.
  • the above-mentioned nucleic acids and vectors expressing nucleic acids complementary thereto can also be used as cell growth inhibitors or growth promoters.
  • a substance that suppresses the expression of a target gene of a nucleic acid such as the above microRNA, or a substance that promotes the expression of the target gene can also be used as a fibrosis inhibitor or a proliferation promoter of cells or organs.
  • a nucleic acid or a vector expressing it can also be used.
  • substances that suppress the expression of the target gene include siRNA against the mRNA of the target gene and antisense to the target gene.
  • Substances that promote the expression of the target gene include those against the target gene-specific microRNA. Examples include siRNA and antisense to the target gene.
  • the preparation form and administration method of the cell or organ fibrosis inhibitor or growth promoter are the same as those for diagnostic agents and therapeutic agents containing nucleic acids such as microRNA and microRNA precursor described later in 10.
  • nucleic acids such as microRNA and microRNA precursors control the expression of genes that have target sequences or control the expression of nucleic acids such as microRNAs By controlling, it can be used as a therapeutic agent for diseases caused by fibrosis of cells or organs, that is, abnormal production of extracellular matrix and EMT.
  • siRNA against the target gene of the nucleic acid controls fibrosis of cells or organs, that is, as a disease caused by abnormal production of extracellular matrix and EMT, etc. Examples include fibrosis associated with tissue damage.
  • a diagnostic agent containing a nucleic acid is a reagent necessary for quantifying a nucleic acid or detecting a mutation, such as a buffer, a salt, a reaction enzyme, a labeled protein that binds to the nucleic acid, depending on the target diagnostic method, And a coloring agent for detection.
  • a therapeutic agent containing a nucleic acid as an active ingredient can be administered alone, but usually mixed with one or more pharmacologically acceptable carriers and well known in the pharmaceutical arts. It is desirable to administer it as a pharmaceutical preparation produced by any method. It is desirable to use the most effective route for treatment, and oral administration or parenteral administration such as buccal, respiratory tract, rectal, subcutaneous, intramuscular and intravenous is desirable. Can be given intravenously.
  • Examples of the dosage form include sprays, capsules, tablets, granules, syrups, emulsions, suppositories, injections, ointments, tapes and the like.
  • Suitable formulations for oral administration include emulsions, syrups, capsules, tablets, powders, granules and the like.
  • Liquid preparations such as emulsions and syrups include sugars such as water, sucrose, sorbitol and fructose, glycols such as polyethylene glycol and propylene glycol, oils such as sesame oil, olive oil and soybean oil, p-hydroxybenzoic acid
  • Preservatives such as esters, and flavors such as strawberry flavor and peppermint can be used as additives.
  • excipients such as lactose, glucose, sucrose, mannitol, disintegrants such as starch and sodium alginate, lubricants such as magnesium stearate and talc, polyvinyl alcohol, hydroxy A binder such as propylcellulose and gelatin, a surfactant such as fatty acid ester, and a plasticizer such as glycerin can be used as additives.
  • Formulations suitable for parenteral administration include injections, suppositories, sprays and the like.
  • the injection is prepared using a carrier made of a salt solution, a glucose solution, or a mixture of both.
  • Suppositories are prepared using a carrier such as cacao butter, hydrogenated fat or carboxylic acid.
  • the spray is prepared using a carrier that does not irritate the recipient's oral cavity and airway mucosa, and that facilitates absorption by dispersing the active ingredient as fine particles.
  • the carrier include lactose and glycerin.
  • a formulation such as an aerosol or dry powder is possible.
  • the components exemplified as additives for oral preparations can also be added.
  • the dose or frequency of administration varies depending on the intended therapeutic effect, administration method, treatment period, age, weight, etc., but is usually 10 ⁇ g / kg to 20 mg / kg per day for an adult.
  • a therapeutic agent containing a nucleic acid as an active ingredient can also be produced by preparing a nucleic acid-expressing vector and a base used for the nucleic acid therapeutic agent [Nature Genet., 8, 42 (1994)].
  • the base used for the therapeutic agent may be any base as long as it is usually used for injections, such as distilled water, sodium chloride or a salt solution such as a mixture of sodium chloride and an inorganic salt, mannitol, lactose, dextran. And a solution such as glucose, an amino acid solution such as glycine and arginine, an organic acid solution or a mixed solution of a salt solution and a glucose solution, and the like.
  • these bases are mixed with an osmotic pressure adjusting agent, a pH adjusting agent, a vegetable oil such as sesame oil and soybean oil, or an auxiliary such as a surfactant such as lecithin or a nonionic surfactant.
  • An injection may be prepared as a suspension or dispersion. These injections can be prepared as preparations for dissolution at the time of use by operations such as pulverization and freeze-drying.
  • the therapeutic agent can be used for treatment as it is in the case of a liquid just before the treatment, or in the case of a solid, dissolved in the above sterilized base if necessary.
  • the nucleic acid-expressing vector examples include the recombinant virus vector prepared by the above method 5, and more specifically, a retrovirus vector and a lentivirus vector.
  • a virus vector can be prepared by combining a nucleic acid with a polylysine-conjugated antibody specific for an adenovirus hexon protein to produce a complex, and binding the resulting complex to an adenovirus vector.
  • the virus vector stably reaches a target cell, is taken up into the cell by an endosome, is degraded in the cell, and the nucleic acid can be efficiently expressed.
  • RNA vectors based on Sendai virus (-) strand RNA virus have also been developed (WO97 / 16538, WO97 / 16539), and using the Sendai virus, a Sendai virus incorporating a nucleic acid can be produced. Can do. Nucleic acids can also be transferred by non-viral nucleic acid transfer methods. For example, calcium phosphate coprecipitation method [Virology, 52 , 456-467 (1973); Science, 209 , 1414-1422 (1980)], microinjection method [Proc. Natl. Acad. Sci. USA, 77 , 5399-5403 ( Proc. Natl. Acad. Sci.
  • nucleic acid can be taken up and expressed locally in the tissue by administering the liposome preparation directly to the target tissue [Hum. Gene Ther., 3 , 399 (1992)].
  • Direct DNA uptake techniques are preferred for targeting DNA directly to a lesion.
  • receptor-mediated DNA transfer can be performed by binding DNA (usually in the form of a covalently closed supercoiled plasmid) to a protein ligand via polylysine. The ligand is selected based on the presence of the corresponding ligand receptor on the cell surface of the target cell or tissue.
  • the ligand-DNA conjugate can be injected directly into the blood vessel, if desired, and can be directed to a target tissue where receptor binding and internalization of the DNA-protein complex occurs.
  • adenovirus can be co-infected to disrupt endosomal function.
  • the method for measuring fibrosis is not particularly limited as long as it is a method capable of measuring increased production of extracellular matrix.
  • staining of extracellular matrix can be used.
  • a method for evaluating the extracellular matrix includes Masson's trichrome staining.
  • the nucleus can be dyed in black with iron hematoxylin, the cytoplasm in red with acidic fuchsin, and the collagen fibers in blue with aniline blue.
  • the blue region and the fibrosis region in the tissue are in a proportional relationship. It is recognized [J Clin Pathol. 59 (4) , 377-81 (2006)].
  • Method for measuring the degree of organ and cell fibrosis As a method for measuring the degree of organ and cell fibrosis, gene expression of the extracellular matrix can be analyzed by quantitative PCR. Specifically, the expression of Collagen and Fibronectin, which are extracellular substrates, is performed by PCR using appropriate reagents such as Syber-Green (QIAGEN) and Taqman-probe (Applied Biosystems), and the fluorescence intensity is measured. Methods and the like. There are also methods for quantifying extracellular matrix by Western blot, ELISA (Enzyme-Linked Immunosorbent Assay) method, colorimetric method and the like. More specifically, Sircol Soluble Collagen Assay (manufactured by Biocolor) and the like can be mentioned.
  • ELISA Enzyme-Linked Immunosorbent Assay
  • fibrosis can be measured only in EMT, which is said to be a particularly important phenomenon in the process of organ and cell fibrosis.
  • Methods for evaluating EMT include reduction of cell markers that are specifically expressed in epithelial cells such as ⁇ -catenin and ZO-1, E-cadherin, and mesenchymal cells such as FSP-1, ⁇ SMA, and Vimentin.
  • quantitative analysis is also possible by analyzing their gene expression by quantitative PCR [J Clin Invest., 117 , 482-91 (2007)].
  • microRNA expression of microRNA during renal fibrosis
  • UUO unilateral ureteral obstruction
  • the left renal ureter of 7-week-old BALB / c mice purchased from Charles River Japan
  • Trizol reagent Invitrogen
  • the product was added to the product.
  • Total RNA was extracted according to the method described.
  • mirVana registered trademark
  • miRNA Bioarrays V9.2 manufactured by Ambion
  • microRNA in the control mouse was set to 1.00, and compared with the expression level of microRNA in the ureter-ligated mouse, the expression was observed in both ureter-ligated mice.
  • Table 5 shows the average value of two urinary ligation mice relative to the control. As shown in Table 5, 31 candidate microRNAs were obtained.
  • mmu_miR_345 is SEQ ID NO: 28
  • hsa_miR_320 is SEQ ID NO: 2
  • hsa_miR_422b corresponds to hsa_miR_378, SEQ ID NO: 3
  • rno_miR_422b corresponds to rno_miR_378, SEQ ID NO: 45
  • hsa_miR_213 is SEQ ID NO: 4
  • mmu_miR_99h is SEQ ID NO: 4
  • hsa_miR_422a is SEQ ID NO: 7
  • hsa_miR_30e_5p is SEQ ID NO: 9
  • hsa_miR_30d is SEQ ID NO: 10
  • hsa_miR_30b is SEQ ID NO: 11
  • hsa_miR_30c is SEQ ID NO: 12
  • the microRNAs indicated by ambi_miR_3998, ambi_miR_7029, ambi_miR_13268, and ambi_miR_13143 are hsa_miR_213 (SEQ ID NO: 4), hsa_miR_451 (SEQ ID NO: 18), hsa_miR_140-3p (SEQ ID NO: 21) registered in miRBase, respectively. This corresponds to hsa_miR_1974 (SEQ ID NO: 23).
  • NRK-49F A rat renal fibroblast cell line, NRK-49F cells (hereinafter referred to as NRK-49F), is a DMEM medium (GIBCO) containing 5% fetal calf serum (GIBCO) and 5% CO 2 at 37 ° C. Cultured in a concentration incubator.
  • NRK-49F was seeded in a 6-well plate at 3 ⁇ 10 4 per well and cultured overnight in the above medium.
  • the medium was replaced with DMEM medium without serum.
  • the medium was replaced with a recombinant human TGF- ⁇ 1 (manufactured by R & D) diluted to a final concentration of 5 ng / ml using DMEM medium without serum, and the culture was continued.
  • the medium was changed to serum-free DMEM not containing TGF- ⁇ 1.
  • the medium was removed, and total RNA was extracted using Trizol reagent (Invitrogen) according to the method described in the product.
  • RNA concentration After measuring the RNA concentration, react with TaqMan MicroRNA assays (Applied Biosystems) according to the method described in the product, and use Real-time PCR with Applied Biosystems 7900HT Fast real-time PCR system (Applied Biosystems). Went.
  • the relative expression level of each control cell was calculated by setting the microRNA expression level of control cells to which TGF ⁇ -1 was not added to 1.00.
  • Table 6 it is clear that miR-378, 192, 30e-5p, 30b, 30c, 30d, 486, 185, 320, 451, 200a, 29c expression is reduced by TGF- ⁇ stimulation. It became.
  • miR-378, 30b, 30c, 486, 451, 29c showed an expression decrease of 50% or more.
  • miR-378 is SEQ ID NO: 3
  • miR-192 is SEQ ID NO: 6
  • miR-30e-5p is SEQ ID NO: 9
  • miR-30d is SEQ ID NO: 10
  • miR-30c is SEQ ID NO: 12
  • miR-30b is SEQ ID NO: 11
  • miR-486 is SEQ ID NO: 14
  • miR-185 is SEQ ID NO: 16
  • miR-320 is SEQ ID NO: 2
  • miR-451 is SEQ ID NO: 18
  • miR-200a is SEQ ID NO: 19
  • miR-29c is SEQ ID NO: The microRNA which has a base sequence represented by 20 is represented.
  • probes represented by human sequences were used for TaqMan MicroRNA assays.
  • MDCK cells which are canine renal epithelial cells.
  • MDCK was seeded in a 24-well plate at 1 ⁇ 10 4 per well and cultured overnight in the above medium. One day later, the medium was replaced with recombinant human TGF- ⁇ 1 (R & D) diluted with DMEM medium containing 10% fetal bovine serum to a final concentration of 10 ng / ml, and the culture was continued. .
  • Trizol reagent Invitrogen
  • TaqMan MicroRNA assays (Applied Biosystems)
  • Applied Biosystems 7900HT Fast real-time PCR system (Applied Biosystems)
  • expression of control cells that do not stimulate TGF- ⁇ and microRNA The amount was compared.
  • the relative expression level of each control cell was calculated by setting the microRNA expression level of the control cells to which TGF- ⁇ 1 was not added to 1.00. As a result, as shown in Table 7, it was revealed that miR-30b, 30c, and 486 expression was reduced by TGF- ⁇ stimulation.
  • miR-146b, 21, 223 expression was increased by TGF- ⁇ stimulation.
  • miR-30b is SEQ ID NO: 11
  • miR-30c is SEQ ID NO: 12
  • miR-486 is SEQ ID NO: 14
  • miR-146b is SEQ ID NO: 25
  • miR-21 is SEQ ID NO: 26
  • miR-223 is SEQ ID NO: The microRNA which has a base sequence represented by 27 is represented.
  • probes represented by human sequences were used for TaqMan MicroRNA assays.
  • Renal fibrosis is known to involve tubule cells, and the cell line NRK-52E is used as a model. Collagen I and the like are used as an index of tubule cell fibrosis [JASN., 16 , 2702-13 (2005)], [Journal of Cellular Biochemistry, 103 , 1999-2009 (2008)].
  • NRK-52E cells (hereinafter referred to as NRK-52E), a rat renal tubular epithelial cell line, are 5% CO at 37 ° C in DMEM medium (GIBCO) containing 5% fetal calf serum (GIBCO). The cells were cultured in a 2 concentration incubator. NRK-52E was seeded in a 24-well plate at 1 ⁇ 10 4 per well and cultured overnight in the above medium. One day later, the final concentration of pre-miR miRNA precursor molecules (Ambion) producing miR-21, 223, 30b, 30c, 486, 194, let-7i was determined by lipofection using lipofectamine 2000 (Invitrogen). Was introduced into NRK-52E to be 5 nM.
  • DMEM medium fetal calf serum
  • MiRNA precursor molecules-Negative control (Ambion) was also introduced as a negative control. Lipofection followed the method described in the instructions attached to the product. 24 hours after the introduction of the molecule by lipofection method, the medium was diluted with DMEM medium containing 5% fetal bovine serum to a final concentration of 2 ng / ml of recombinant human TGF- ⁇ 1 (R & D). The culture was continued. Two days after changing to a medium containing TGF- ⁇ 1, the medium was removed, and using Trizol reagent (Invitrogen), total RNA was extracted according to the method described in the product.
  • Trizol reagent Invitrogen
  • cDNA was synthesized according to the method described in the product.
  • the expression of fibrosis-related genes was analyzed by real-time RT-PCR.
  • Samples were prepared using the QuantiTect SYBR Green PCR Kit (QIAGEN) according to the method described in the product, and the expression level of collagen I was quantified using an Applied Biosystems 7900HT Fast real-time PCR system (Applied Biosystems).
  • fibroblasts forced to express microRNAs on extracellular matrix production Pre-miR miRNA precursor molecules (Ambion) were introduced into fibroblasts, and the effects of microRNAs generated from these molecules on collagen production were examined. It was. Renal fibrosis is known to involve fibroblasts in kidney tissue, and the model cell line NRK-49F is used as the model. Collagen I or the like is used as an index of fibrosis [JASN., 16 , 2702-13 (2005)], [Kidney International, 66 , 112-120 (2004)]. NRK-49F was seeded in a 24-well plate at 2 ⁇ 10 4 per well and cultured overnight in the above medium.
  • pre-miR miRNA precursor molecules that produce miR-21, 30b, 30c, 192, 486, let-7i is 5 nM by lipofection using lipofectamine 2000 (Invitrogen). Introduced into NRK-49F. MiRNA precursor molecules-Negative control (Ambion) was also introduced as a negative control. Lipofection followed the method described in the instructions attached to the product. Eight hours after the introduction of the molecule by the lipofection method, the medium was replaced with serum-free DMEM medium.
  • the medium was replaced with recombinant human TGF- ⁇ 1 (R & D) diluted to a final concentration of 1 ng / ml using DMEM medium without serum, and the culture was continued.
  • TGF- ⁇ 1 recombinant human TGF- ⁇ 1
  • the medium was removed, and using Trizol reagent (Invitrogen), total RNA was extracted according to the method described in the product.
  • Trizol reagent Invitrogen
  • total RNA was extracted according to the method described in the product.
  • PrimeScript 1st strand cDNA Synthesis Using Kit manufactured by Takara Bio Inc.
  • cDNA was synthesized according to the method described in the product.
  • the expression of fibrosis-related genes was analyzed by real-time RT-PCR.
  • MDCK epithelial-mesenchymal transition
  • ⁇ SMA ⁇ smooth muscle actin
  • MDCK was seeded in a 24-well plate at 1 ⁇ 10 4 per well and cultured overnight in the above medium.
  • pre-miR miRNA precursor molecules that generate miR-21, 146b, 223, 194, let-7i were made MDCK to a final concentration of 5 nM by lipofection using lipofectamine 2000 (Invitrogen). Introduced.
  • MiRNA precursor molecules-Negative control (Ambion) was also introduced as a negative control. Lipofection followed the method described in the instructions attached to the product. 24 hours after introduction of the molecule by the lipofection method, the medium was diluted with DMEM medium containing 10% fetal calf serum to a final concentration of 2 ng / ml of recombinant human TGF- ⁇ 1 (R & D). The culture was continued. Two days after replacement with a medium containing TGF- ⁇ 1, the medium was removed, and using Trizol reagent (Invitrogen), total RNA was extracted according to the method described in the product.
  • Trizol reagent Invitrogen
  • Li-90 cells which are human hepatic stellate cells, are DMEM medium (GIBCO) containing 20% fetal calf serum (GIBCO) and a 5% CO 2 concentration at 37 ° C.
  • the medium was replaced with recombinant human TGF- ⁇ 1 (manufactured by R & D) diluted to a final concentration of 1 ng / ml using DMEM medium without serum, and the culture was continued.
  • TGF- ⁇ 1 manufactured by R & D
  • Trizol reagent Invitrogen
  • total RNA was extracted according to the method described in the product.
  • cDNA was synthesized using superscript VILO (Invitrogen) according to the method described in the product. Using the prepared cDNA, the expression of fibrosis-related genes was analyzed by real-time RT-PCR.
  • microRNA effects of microRNA on forced extracellular matrix production of pulmonary fibroblasts
  • Pre-miR miRNA precursor molecules manufactured by Ambion
  • fibroblasts in lung tissue are involved in lung fibrosis, and collagen I and the like are used as an index of the fibrosis [Respiration, 77 , 311-319 (2009) ].
  • IMR-90 Human lung fibroblast IMR-90 cells
  • IMR-90 Human lung fibroblast IMR-90 cells
  • MEM medium containing 10% fetal calf serum (GIBCO), 2 mM L-glutamine, 0.1 mM NEAA, 1 mM pyruvate ( (Manufactured by GIBCO) at 37 ° C. in an incubator with 5% CO 2 concentration.
  • IMR-90 was seeded in a 24-well plate at 1.5 ⁇ 10 4 per well and cultured overnight in the above medium.
  • pre-miR miRNA precursor molecules that generate miR-30b, 30c, 486, and let-7i were added to IMR-90 by lipofection using lipofectamine 2000 (Invitrogen) to a final concentration of 10 nM. Introduced. MiRNA precursor molecules-Negative control (Ambion) was also introduced as a negative control. Lipofection followed the method described in the instructions attached to the product. Eight hours after the introduction of the molecule by the lipofection method, the medium was replaced with a serum-free MEM medium.
  • the medium was replaced with a recombinant human TGF- ⁇ 1 (manufactured by R & D) diluted to a final concentration of 0.5 ng / ml using DMEM medium without serum, and the culture was further continued.
  • TGF- ⁇ 1 human TGF- ⁇ 1
  • Trizol reagent Invitrogen
  • total RNA was extracted according to the method described in the product.
  • cDNA was synthesized using superscript VILO (Invitrogen) according to the method described in the product. Using the prepared cDNA, the expression of fibrosis-related genes was analyzed by real-time RT-PCR.
  • anti-miR miRNA inhibitors that inhibit miR-30c, 486, 320a, 378, and 451 were introduced into NRK-52E by lipofection using lipofectamine 2000 (Invitrogen) to a final concentration of 30 nM. did.
  • Anti-miR miRNA Inhibitors-Negative Control # 1 (Ambion) was also introduced as a negative control. Lipofection followed the method described in the instructions attached to the product. 24 hours after introduction of the molecule by the lipofection method, the medium was diluted with DMEM medium containing 5% fetal calf serum to a final concentration of 2 ng / ml of recombinant human TGF- ⁇ 1 (R & D) The culture was continued.
  • miR-320a SEQ ID NO: 2
  • miR-378 SEQ ID NO: 3
  • miR-30c SEQ ID NO: 12
  • miR-486 SEQ ID NO: 14
  • miR-451 It was revealed that the expression of collagen I was increased by suppressing the expression of SEQ ID NO: 18).
  • anti-miR miRNA inhibitors that inhibit miR-30c, 192, 320a, 378, and 451 were introduced into NRK-49F by lipofection using lipofectamine 2000 (Invitrogen) to a final concentration of 30 nM. did.
  • Anti-miR miRNA Inhibitors-Negative Control # 1 was also introduced as a negative control. Lipofection followed the method described in the instructions attached to the product. For let-7i and miR-486, miRIDIAN microRNA Hairpin Inhibitor (manufactured by Dharmacon) was introduced into NRK-49F by a lipofection method using lipofectamine 2000 to a final concentration of 10 nM.
  • MiRIDIAN microRNA Hairpin Inhibitor Negative Control # 2 (Dharmacon) was also introduced as a negative control. Eight hours after the introduction of the molecule by the lipofection method, the medium was replaced with serum-free DMEM medium. After another 16 hours, the medium was replaced with a recombinant human TGF- ⁇ 1 (manufactured by R & D) diluted to a final concentration of 1 ng / ml using DMEM medium without serum, and the culture was further continued. Two days after replacement with a medium containing TGF- ⁇ 1, the medium was removed, and using Trizol reagent (Invitrogen), total RNA was extracted according to the method described in the product.
  • Trizol reagent Invitrogen
  • miR-320a SEQ ID NO: 2
  • miR-378 SEQ ID NO: 3
  • miR-192 SEQ ID NO: 6
  • miR-30c SEQ ID NO: 12
  • miR-486 It was revealed that the expression of collagen I was increased by suppressing the expression of SEQ ID NO: 14), miR-451 (SEQ ID NO: 18), and let-7i (SEQ ID NO: 8).
  • Anti-miR miRNA Inhibitors-Negative Control # 1 was also introduced as a negative control. Lipofection followed the method described in the instructions attached to the product. 24 hours after introduction of the molecule by the lipofection method, the medium was diluted with DMEM medium containing 10% fetal bovine serum to a final concentration of 2 ng / ml of recombinant human TGF- ⁇ 1 (R & D). The culture was continued. Two days after replacement with a medium containing TGF- ⁇ 1, the medium was removed, and using Trizol reagent (Invitrogen), total RNA was extracted according to the method described in the product.
  • Trizol reagent Invitrogen
  • miR-320a SEQ ID NO: 2
  • miR-378 SEQ ID NO: 3
  • miR-192 SEQ ID NO: 6
  • miR-30c SEQ ID NO: 12
  • miR-486 It was revealed that the expression of ⁇ SMA was increased by suppressing the expression of SEQ ID NO: 14) and miR-451 (SEQ ID NO: 18).
  • microRNA administration on organ fibrosis
  • the microRNAs evaluated were miR-30b, miR-486, and let-7i.
  • miR-30b uses a nucleic acid (hsa-miR-30b) consisting of the base sequence represented by SEQ ID NO: 11 as an antisense strand, and is complementary to the first base to the 19th base on the 5 ′ side of the antisense strand.
  • miR-486 is obtained by annealing an antisense strand consisting of the base sequence represented by SEQ ID NO: 14 and a sense strand consisting of the base sequence represented by SEQ ID NO: 1283
  • let-7i is SEQ ID NO: 8
  • An antisense strand consisting of the base sequence represented by the above and an annealed sense strand consisting of the base sequence represented by SEQ ID NO: 1284 were used.
  • 21mer luciferase siRNA was used as a negative control.
  • RNA was synthesized by Hokkaido System Science and described in Stable nucleic acid lipid particle (SNALP), a lipid particle with high delivery efficiency to the liver, described in Mol Ther., 13 (3) , 494-505 (2006). After conjugation according to the established method, it was used for evaluation. Hepatology, 50 , 185-197 (2009), Am J Physiol Gastrointest Liver Physiol, 296 , G582-G592 using the Bile Duct Ligation (BDL) model known as a general animal model for liver fibrosis (2009)].
  • BDL Bile Duct Ligation
  • Bile ducts from 9-week-old male C57BL / 6J mice purchased from Charles River Japan were ligated under anesthesia and 7 SNALP conjugate microRNAs were administered at a dose of 150 ⁇ g / head immediately after surgery and 24 hours later, respectively. Administered. Thereafter, the liver was removed 48 hours later and quickly frozen in liquid nitrogen. Frozen liver is crushed using Trizol reagent (Invitrogen), added with chloroform (Wako Pure Chemicals) and centrifuged, and then the supernatant is described in the product using RNeasy kit (QIAGEN) Total RNA was extracted according to the method described.
  • cDNA was synthesized using Super Script VILO TM cDNA Synthesis Kit (manufactured by Invitrogen) according to the method described in the product.
  • Super Script VILO TM cDNA Synthesis Kit manufactured by Invitrogen
  • the expression of fibrosis-related genes was analyzed by real-time RT-PCR.
  • the expression level of TGF- ⁇ 1 was quantified.
  • an agent for controlling fibrosis of cells or organs a diagnostic or therapeutic agent for diseases caused by fibrosis of cells or organs, an agent for controlling expression of target genes of nucleic acids such as microRNA, a method for controlling cells or organs,
  • screening methods for cell or organ fibrosis control agents and the like are provided, which are useful in the prevention, diagnosis or treatment of diseases caused by cell or organ fibrosis.
  • control refers to suppression and promotion.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur un acide nucléique et un agent de contrôle de la fibrose qui sont utiles dans le contrôle de la fibrose de cellules ou d'organes. L'invention porte également sur un procédé d'utilisation dudit acide nucléique et dudit agent de contrôle de la fibrose. L'invention porte également sur ce qui suit : un acide nucléique contenant une séquence de base représentée par l'une des séquences numéros 1 à 1281 ; un acide nucléique identique à au moins 90 % à l'acide nucléique mentionné ci-dessus ; un acide nucléique hybridé avec un brin complémentaire de l'acide nucléique mentionné ci-dessus dans des conditions stringentes ; un acide nucléique contenant la seconde à la huitième séquence de base d'une séquence de base représentée par l'une des séquences numéros 1 à 594 ; un agent de contrôle de la fibrose de cellules ou d'organes utilisant un acide nucléique ou similaire comprenant une séquence de base qui est complémentaire de la séquence de base d'un acide nucléique mentionné ci-dessus ; un agent de diagnostic ou thérapeutique pour les troubles résultant de la fibrose de cellules ou d'organes ; un agent de contrôle de l'expression pour des gènes cibles d'acides nucléiques tels que des microARN ; un procédé de contrôle ou similaire pour des cellules ou des organes ; et un procédé de ciblage d'agents de contrôle de la fibrose de cellules ou d'organes.
PCT/JP2010/063728 2009-08-12 2010-08-12 Acide nucléique qui contrôle la fibrose de cellules ou d'organes Ceased WO2011019074A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009-187563 2009-08-12
JP2009187563 2009-08-12

Publications (1)

Publication Number Publication Date
WO2011019074A1 true WO2011019074A1 (fr) 2011-02-17

Family

ID=43586248

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2010/063728 Ceased WO2011019074A1 (fr) 2009-08-12 2010-08-12 Acide nucléique qui contrôle la fibrose de cellules ou d'organes

Country Status (1)

Country Link
WO (1) WO2011019074A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011217617A (ja) * 2010-04-05 2011-11-04 Kyoto Univ ｍｉＲＮＡを利用した慢性肝疾患の線維化の検査方法
CN109852597A (zh) * 2019-03-21 2019-06-07 云南师范大学 一种β-半乳糖苷酶galRBM20_1及其制备方法和应用
JP2019187413A (ja) * 2018-04-23 2019-10-31 チャン グァン メモリアル ホスピタル，カオシュン ループス腎炎の検出またはそのリスクを予測する方法およびその応用
WO2019246499A1 (fr) * 2018-06-21 2019-12-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Systèmes et procédés pour déterminer un déroulement d'action de traitement
CN114015763A (zh) * 2021-10-13 2022-02-08 深圳市人民医院 miR-378-5p在系膜增生性肾小球肾炎中的应用
WO2022219404A1 (fr) * 2021-04-13 2022-10-20 Oslo Universitetssykehus Hf Thérapie génique pour états inflammatoires

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009018493A1 (fr) * 2007-07-31 2009-02-05 The Board Of Regents Of The University Of Texas System Famille de micro-arn modulant une fibrose et procédés d'utilisation associés

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009018493A1 (fr) * 2007-07-31 2009-02-05 The Board Of Regents Of The University Of Texas System Famille de micro-arn modulant une fibrose et procédés d'utilisation associés

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DUISTERS, R.F. ET AL.: "miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling", CIRC RES, vol. 104, 18 December 2008 (2008-12-18), pages 170 - 178, XP008102625, DOI: doi:10.1161/CIRCRESAHA.108.182535 *
KATO, M. ET AL.: "TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN", NAT CELL BIOL, vol. 11, 21 June 2009 (2009-06-21), pages 881 - 889, XP055026246, DOI: doi:10.1038/ncb1897 *
LI, M. ET AL.: "MicroRNAs: control and loss of control in human physiology and disease", WORLD J SURG, vol. 33, no. 4, 22 November 2008 (2008-11-22), pages 667 - 684, XP019707084 *
LI, Z. ET AL.: "Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation", J BIOL CHEM, vol. 284, 2 April 2009 (2009-04-02), pages 15676 - 15684, XP055038948, DOI: doi:10.1074/jbc.M809787200 *
ROOIJ, E.V. ET AL.: "Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis", PROC NATL ACAD SCI U S A, vol. 105, 22 August 2008 (2008-08-22), pages 13027 - 13032, XP002571306, DOI: doi:10.1073/pnas.0805038105 *
ROOIJ, E.V. ET AL.: "Searching for miR-acles in cardiac fibrosis", CIRC RES, vol. 104, 30 January 2009 (2009-01-30), pages 138 - 140, XP002591350, DOI: doi:10.1161/CIRCRESAHA.108.192492 *
THUM, T. ET AL.: "MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts", NATURE, vol. 456, 30 November 2008 (2008-11-30), pages 980 - 984 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011217617A (ja) * 2010-04-05 2011-11-04 Kyoto Univ ｍｉＲＮＡを利用した慢性肝疾患の線維化の検査方法
JP2019187413A (ja) * 2018-04-23 2019-10-31 チャン グァン メモリアル ホスピタル，カオシュン ループス腎炎の検出またはそのリスクを予測する方法およびその応用
WO2019246499A1 (fr) * 2018-06-21 2019-12-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Systèmes et procédés pour déterminer un déroulement d'action de traitement
US12351877B2 (en) 2018-06-21 2025-07-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Systems and methods for determining a treatment course of action
CN109852597A (zh) * 2019-03-21 2019-06-07 云南师范大学 一种β-半乳糖苷酶galRBM20_1及其制备方法和应用
WO2022219404A1 (fr) * 2021-04-13 2022-10-20 Oslo Universitetssykehus Hf Thérapie génique pour états inflammatoires
CN114015763A (zh) * 2021-10-13 2022-02-08 深圳市人民医院 miR-378-5p在系膜增生性肾小球肾炎中的应用

Similar Documents

Publication Publication Date Title
EP2208499A1 (fr) Acide nucléique capable de réguler la prolifération d'une cellule
AU2007334502B2 (en) Compositions and methods to treat muscular & cardiovascular disorders
WO2009148137A1 (fr) Acide nucléique capable de réguler la dégranulation d'un mastocyte
EP2077326A1 (fr) Nouvel acide nucléique
EP2794881B1 (fr) Miarn pour le traitement du cancer de la tête et du cou
JPWO2008084319A1 (ja) 新規核酸
WO2011019074A1 (fr) Acide nucléique qui contrôle la fibrose de cellules ou d'organes
EP2464730B1 (fr) Composés de miARN pour le traitement du carcinome de la prostate
WO2011111715A1 (fr) Acide nucléique apte à réguler le cycle cellulaire
EP2852669B1 (fr) Cibles thérapeutiques micro arn dans des maladies pulmonaires chroniques
JPWO2010079819A1 (ja) 肥満または糖尿病治療用医薬組成物
US20100305195A1 (en) microrna mediator of cardiomyopathy and heart failure
EP4667571A1 (fr) Construction de miarn artificiel
KR101993894B1 (ko) 마이크로 rna를 포함하는 이중나선 올리고 rna 구조체
WO2011010737A1 (fr) Acide nucléique guide utilisé dans le clivage de micro-arn
JP2011190176A (ja) 肥満細胞の脱顆粒抑制剤
HK1192280A (en) Micro-rna mir-145 that regulate muscle cell proliferation and differentiation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10808257

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10808257

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP